Stocktoria
MiNK Therapeutics, Inc. INKT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-10-15
MiNK Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $5.8M | $6.3M | $15.5M | $23.1M | $14.0M |
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Interest expense | -$110,000 | -$93,000 | -$28,000 | — | $2.4M |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M |
| EPS (diluted) | $-2.93 | $-2.86 | $-6.54 | $-0.83 | $-1.16 |
| Operating cash flow | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Free cash flow | — | — | -$15.8M | -$19.1M | -$13.1M |
| Cash & equivalents | $13.4M | $4.6M | $3.4M | $19.6M | $38.9M |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
| Shareholders' equity | -$14.2M | -$19.6M | -$18.1M | -$401,303 | $23.8M |
Source: SEC EDGAR filings · CIK 0001840229 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.